Dr. Lee S. Stein, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Georgia College of Eclectric Medicine and Surgery (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 564
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: Georgia College of Eclectric Medicine and Surgery
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TN license MD16177
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospitals of Memphis Memphis, TN
- Baptist Memorial Hospital Memphis, TN
- North Mississippi Medical Center Tupelo, MS
- Baptist Memorial Hospital Desoto Southaven, MS
- Magnolia Regional Health Center Corinth, MS
Medical groups
- Neurology Clinic, PC (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 564
- Services billed
- 24,260
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, gadoterate meglumine, 0.1 ml | 10,550 | 70 |
| Established patient office or other outpatient visit, 30-39 minutes | 613 | 362 |
| Established patient office or other outpatient visit, 20-29 minutes | 186 | 150 |
| New patient office or other outpatient visit, 30-44 minutes | 99 | 99 |
| Mri scan of brain without contrast | 75 | 74 |
| Mri scan of brain before and after contrast | 66 | 64 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 45 | 11 |
| Mri scan of upper spinal canal before and after contrast | 26 | 25 |
| Administration of chemotherapy into vein, 1 hour or less | 23 | 11 |
| Established patient office or other outpatient visit, 10-19 minutes | 21 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Memantine Hcl Other prescribers in Cordova, TN | 312 |
| Gabapentin Other prescribers in Cordova, TN | 281 |
| Clonazepam Other prescribers in Cordova, TN | 151 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Cordova, TN | 148 |
| Tizanidine Hcl Other prescribers in Cordova, TN | 118 |
| Dalfampridine Er (dalfampridine) | 118 |
| Primidone Other prescribers in Cordova, TN | 103 |
| Donepezil Hcl Other prescribers in Cordova, TN | 103 |
| Rivastigmine Other prescribers in Cordova, TN | 101 |
| Nortriptyline Hcl Other prescribers in Cordova, TN | 92 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 32 companies reported 194 payments worth $3,768 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $392 |
|---|---|
| UCB, Inc. | $383 |
| AbbVie Inc. | $311 |
| Tg Therapeutics, Inc. | $231 |
| Argenx US, Inc. | $202 |
| Neurocrine Biosciences, Inc. | $187 |
| Csl Behring | $162 |
| Pfizer Inc. | $152 |
| Food and Beverage | $3,521 |
|---|---|
| Education | $247 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Nov 26, 2025 | Education in-kind | $99.99 |
| Teva Pharmaceuticals USA, Inc. Dec 20, 2025 | Education in-kind | $88.49 |
| Csl Behring Apr 25, 2025 | Education Hizentra · Immunology · in-kind | $11.71 |
| Csl Behring May 19, 2025 | Education Hizentra · Immunology · in-kind | $11.71 |
| Csl Behring Jun 10, 2025 | Education Hizentra · Immunology · in-kind | $11.71 |
| Csl Behring Jun 18, 2025 | Education Hizentra · Immunology · in-kind | $11.71 |
| Csl Behring Sep 30, 2025 | Education Hizentra · Immunology · in-kind | $11.71 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $487,344 in research payments for these studies, mostly to the institutions running them.
- A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc. - Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205
Biogen, Inc. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - Ocrelizumab SC Phase III
Genentech, Inc. - Ocrelizumab PPMS High Dose Study
Genentech, Inc. - A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Novartis Pharmaceuticals Corporation - Ocrevus Subcutaneous Study for Safety and Tolerability
Genentech, Inc. - OCARINA I
Genentech, Inc. - A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Biogen, Inc. - A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
ModernaTX, Inc. · Recruiting · NCT06735248
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.